The Plasmodium Liver-Specific Protein 2 (LISP2) is an early marker of liver stage development
- Novartis Institute for Tropical Diseases, United States
- Université des Sciences, des Techniques et des Technologies de Bamako, Mali
- Biomedical Primate Research Centre, Netherlands
- Novartis Institutes for BioMedical Research, Switzerland
- Novartis Institute for Tropical Diseases, Singapore
- Center for Infectious Disease Research, United States
- Mahidol University, Thailand
- Ehime University, Japan
Abstract
Plasmodium vivax hypnozoites persist in the liver, cause malaria relapse and represent a major challenge to malaria elimination. Our previous transcriptomic study provided a novel molecular framework to enhance our understanding of the hypnozoite biology (Voorberg-van der Wel A, et al., 2017). In this dataset, we identified and characterized the Liver-Specific Protein 2 (LISP2) protein as an early molecular marker of liver stage development. Immunofluorescence analysis of hepatocytes infected with relapsing malaria parasites, in vitro (P. cynomolgi) and in vivo (P. vivax), reveals that LISP2 expression discriminates between dormant hypnozoites and early developing parasites. We further demonstrate that prophylactic drugs selectively kill all LISP2 positive parasites, while LISP2 negative hypnozoites are only sensitive to anti-relapse drug tafenoquine. Our results provide novel biological insights in the initiation of liver stage schizogony and an early marker suitable for the development of drug discovery assays predictive of anti-relapse activity.
Data availability
All data generated during the study are submitted as supplementary source files.
-
Malaria Liver Stages TranscriptomeNCBI Sequence Read Archive, SRP096160.
Article and author information
Author details
Annemarie Voorberg-van der Wel
Jetsumon Sattabongkot
Thierry Tidiane Diagana
Funding
Bill and Melinda Gates Foundation (OPP1141292)
- Guglielmo Roma
- Clemens H M Kocken
- Thierry Tidiane Diagana
Bill and Melinda Gates Foundation (OPP1137694)
- Sebastian A Mikolajczak
Funders have no role in the design of the study.
Ethics
Animal experimentation: Ethics statement included in the method section of the manuscript.
Copyright
© 2019, Gupta et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,860
- views
-
- 460
- downloads
-
- 51
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
The Plasmodium Liver-Specific Protein 2 (LISP2) is an early marker of liver stage development
eLife 8:e43362.
https://doi.org/10.7554/eLife.43362
Further reading
-
- Microbiology and Infectious Disease
eLife has recently published a wide range of papers on malaria, covering a diversity of themes including parasite biology, epidemiology, immunology, drugs and vaccines.
-
- Evolutionary Biology
- Microbiology and Infectious Disease
Accurate estimation of the effects of mutations on SARS-CoV-2 viral fitness can inform public-health responses such as vaccine development and predicting the impact of a new variant; it can also illuminate biological mechanisms including those underlying the emergence of variants of concern. Recently, Lan et al. reported a model of SARS-CoV-2 secondary structure and its underlying dimethyl sulfate reactivity data (Lan et al., 2022). I investigated whether base reactivities and secondary structure models derived from them can explain some variability in the frequency of observing different nucleotide substitutions across millions of patient sequences in the SARS-CoV-2 phylogenetic tree. Nucleotide basepairing was compared to the estimated ‘mutational fitness’ of substitutions, a measurement of the difference between a substitution’s observed and expected frequency that is correlated with other estimates of viral fitness (Bloom and Neher, 2023). This comparison revealed that secondary structure is often predictive of substitution frequency, with significant decreases in substitution frequencies at basepaired positions. Focusing on the mutational fitness of C→U, the most common type of substitution, I describe C→U substitutions at basepaired positions that characterize major SARS-CoV-2 variants; such mutations may have a greater impact on fitness than appreciated when considering substitution frequency alone.
